Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows provided by operating activities:
Net income	$ 516	$ 1,041
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	85	83
Amortization of operating lease right-of-use assets	126	120
Stock based compensation	37	8
Change in deferred tax assets	(38)	277
Realized gain on sale of investment in iBio Stock	0	(56)
Unrealized loss on investment in iBio Stock	20	29
Other, Net	2	5
Changes in operating assets and liabilities:
Accounts receivable, net	1,975	652
Inventories	(927)	(2,655)
Other current assets	(202)	(185)
Security deposits and other assets	0	(26)
Accounts payable	771	2,696
Accrued expenses and other liabilities	(138)	49
Operating lease obligations	(126)	(120)
Net cash provided by operating activities	2,101	1,918
Cash flows from investing activities:
Purchase of property and equipment	(131)	(53)
Proceeds from sale of iBio Stock	0	96
Net cash (used in) provided by investing activities	(131)	43
Cash flows from financing activities:
Advances under revolving credit facility	14,029	13,921
Proceeds from exercise of stock options	4	0
Repayments of advances under revolving credit facility	(14,830)	(15,144)
Repayments under term note payables	(1,326)	(734)
Repayments under finance lease obligations	0	(37)
Net cash used in financing activities	(2,123)	(1,994)
Net decrease in cash	(153)	(33)
Cash at beginning of period	210	402
Cash at end of period	57	369
Supplemental disclosures of cash flow information:
Interest paid	30	57
Income taxes paid	0	0
Supplemental disclosures of non-cash flow transactions:
Amount owed on purchase of property and equipment	$ 45	$ 20